Blueshift Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Blueshift Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,345	Closed	-$222K	–	365
2024 Q2	$222K	Buy	+5,345	New	+$239K	0.07%	304
2024 Q1	–	Sell	-4,214	Closed	-$216K	–	278
2023 Q4	$216K	Buy	+4,214	New	+$221K	0.11%	227
2023 Q3	–	Sell	-3,428	Closed	-$219K	–	288
2023 Q2	$219K	Sell	3,428 -2,726	-44%	-$183K	0.08%	284
2023 Q1	$427K	Buy	6,154 +177	+3%	+$12.5K	0.18%	159
2022 Q4	$430K	Buy	+5,977	New	+$451K	0.2%	147
2022 Q2	–	Sell	-27,124	Closed	-$1.98M	–	702
2022 Q1	$1.98M	Buy	+27,124	New	+$1.82M	0.18%	147
2021 Q4	–	Sell	-249,521	Closed	-$14.8M	–	870
2021 Q3	$14.8M	Buy	249,521 +227,131	+1,014%	+$15M	0.83%	6
2021 Q2	$1.5M	Buy	22,390 +131	+0.6%	+$8.54K	0.08%	269
2021 Q1	$1.41M	Buy	+22,259	New	+$1.38M	0.14%	192
2020 Q1	–	Sell	-52,025	Closed	-$3.34M	–	237
2019 Q4	$3.34M	Buy	+52,025	New	+$2.98M	0.38%	48

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Blueshift Asset Management's BMY Position: Q3 2024 in Review

Blueshift Asset Management sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 5,345 shares — an estimated $222K sold.

Blueshift Asset Management first reported a position in BMY in Q4 2019 and held it in 10 quarters. The position peaked at $14.8M in Q3 2021. 2,263 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Blueshift Asset Management reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
Blueshift Asset Management sold 5,345 Bristol-Myers Squibb shares in Q3 2024, an estimated $222K.
Blueshift Asset Management first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 10 quarters.
Blueshift Asset Management's Bristol-Myers Squibb position peaked at $14.8M in Q3 2021.
2,263 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Blueshift Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.